Year: 2025

Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose selection for potential Phase 3 development program; initial clinical data expected in 2H 2026  Recent significant corporate milestones include the selection of a CDMO, CFO hire, and opening of corporate headquarters Cash, cash equivalents and short-term investments of $77.0M as of September 30, 2025, expected to fund operations into 2027 Kalaris is currently evaluating TH103, a dual-targeting biologic designed to achieve superior VEGF inhibition and extended intraocular durability through optimized binding to VEGF receptor 1 ligands and concurrent heparan sulfate proteoglycan (HSPG) anchoring BERKELEY HEIGHTS, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE)...

Encouraging Clinical Progress, Including Positive Interim Phase 2 Results for the Treatment of Cancer Anorexia Cachexia Syndrome SOLANA BEACH, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended September 30, 2025. “We continue to deliver on our clinical and strategic objectives, advancing three differentiated programs with strong potential to address large, underserved markets,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “We were very pleased with the interim Phase...

Presented robust CRB-701 clinical data at ESMO 2025 – 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUC CRB-701 HNSCC registrational study planned to start mid-2026 Completed $75 million public offering, extending cash runway into 2028 Expected to complete CRB-913 SAD/MAD study and initiate Ph1b study in obese patients in Q4 2025NORWOOD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today provided a corporate update and reported financial results for the quarter ended September 30, 2025. “This has been a productive period for Corbus, led by the presentation of CRB-701 data at ESMO 2025,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “We are encouraged...

Updated clinical results from Phase 2 pivotal portion of the PYNNACLE study evaluating rezatapopt featured in late-breaking oral presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 34% overall response rate (ORR) observed among 103 evaluable patients across all cohorts with a median duration of response of 7.6 months 46% ORR observed among 48 evaluable patients in ovarian cancer cohort with a median duration of response of 8.0 months Rezatapopt New Drug Application submission for platinum resistant/refractory ovarian cancer planned in first quarter of 2027 Cash, cash equivalents, and marketable securities of $129.3 million as of September 30, 2025, providing expected cash runway to end of first quarter of 2027PRINCETON, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) — PMV Pharmaceuticals,...

Leveraging AI Efficiencies Reduced Quarterly Operating Expenses from $22M to $6M, Reduced Staff from 350 to 95 LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) — LiveOne (Nasdaq: LVO), a leading music, entertainment, and social platform delivering premium livestreams, digital media, and original content worldwide, announced today its financial results for the second quarter (“Q2 Fiscal 2026”) and first six months (“1H Fiscal 2026”) of its fiscal year ending March 31, 2026 (“Fiscal 2026”). LiveOne will host a conference call and webcast today, November 12, 2025. Financial HighlightsQ2 Fiscal 2026 Revenue: $18.8 million Audio Division Q2 Fiscal 2026 Revenue: Over $18 million, maintaining positive segment Adjusted EBITDA* of $0.7 million PodcastOne Fiscal 2026 Guidance: Revenue of $56–60 million and Adjusted EBITDA* of $4.5–6...

– Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial presented at the European Society for Medical Oncology (ESMO) Annual Congress 2025 – – Next generation oncolytic virus VCN-12 preclinical data presented at the 32nd Annual Congress European Society of Gene & Cell Therapy (ESGCT) – – Cash and cash equivalents of $7.5 millon as of September 30, 2025; recent capital raises increase cash to $15.5 million as of November 10, 2025 and extends cash runway into Q1 2027 – ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported...

Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsy Further fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors $106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) — – Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ended September 30, 2025 and provided a business update. Net loss was $10.8 million, or $0.22 per share, compared to net loss of $27.9 million,...

HOUSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) — U.S. Energy Corporation (NASDAQ: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in the development and operation of high-quality producing energy and industrial gas assets, today reported financial and operating results for the three and nine months ended September 30, 2025. MANAGEMENT COMMENTS “U.S. Energy delivered another quarter of meaningful operational progress in Q3 2025 as we advanced our Montana industrial gas project,” said Ryan Smith, CEO. “With disciplined execution across upstream development, infrastructure build-out, and carbon management, the Kevin Dome’s scale and strategic location continue to position us as a first mover in a rapidly expanding segment of the energy market. Design of our initial processing facility is now complete, with...

LAS VEGAS, Nov. 12, 2025 (GLOBE NEWSWIRE) — TON Strategy Company (“TON Strategy” or the “Company”) (Nasdaq: TONX), a digital asset treasury company dedicated to holding Toncoin ($TON), today reported financial results for the third quarter ended September 30, 2025 and provided an update on the Company’s TON treasury operations. TON Strategy is a digital asset treasury and Web3 ecosystem company focused on supporting The Open Network (TON), a public Layer-1 blockchain designed to integrate directly with Telegram, where more than 1 billion monthly active users communicate, transact, and build communities. TON provides the rails for payments, digital property, stablecoins, and decentralized mini applications inside the Telegram messaging ecosystem. In August 2025, the Company initiated its TON Treasury Strategy. Proceeds from the...

MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today provided corporate updates and third quarter 2025 financial results. “The past quarter delivered breakthrough progress on every front,” said Maria Maccecchini, Ph.D., President and CEO of Annovis. “Our pivotal Phase 3 Alzheimer’s study has achieved full activation across all clinical sites, with enrollment momentum advancing every day. We have fortified our intellectual property position by transferring all patents to our new crystal form of buntanetap while publishing compelling pharmacokinetic...